Holen Sie sich die Stockscreener-App
4.73
1.50%
0.07
Handel nachbörslich:
4.73
Schlusskurs vom Vortag:
$4.66
Offen:
$4.59
24-Stunden-Volumen:
1.47M
Relative Volume:
0.54
Marktkapitalisierung:
$728.71M
Einnahmen:
$181.41M
Nettoeinkommen (Verlust:
$-59.56M
KGV:
-11.26
EPS:
-0.42
Netto-Cashflow:
$-38.83M
1W Leistung:
+0.42%
1M Leistung:
-6.34%
6M Leistung:
+36.71%
1J Leistung:
+129.61%
1-Tages-Spanne:
$4.52
$4.77
1-Wochen-Bereich:
$4.52
$4.90
52-Wochen-Spanne:
$2.04
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Branche
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Vergleichen Sie XERS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
4.73 | 728.71M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing - Seeking Alpha
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying Activity - Defense World
Pallas Capital Advisors LLC Acquires New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Squarepoint Ops LLC Has $138,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Two Sigma Advisers LP Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings - Defense World
Leerink Partnrs Forecasts Lower Earnings for Xeris Biopharma - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 5.5%Should You Sell? - MarketBeat
Leerink Partners raises Xeris Pharmaceuticals stock price target By Investing.com - Investing.com UK
Transcript : Xeris Biopharma Holdings, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 01 - MarketScreener
Xeris at Jefferies Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada
xeris biopharma holds annual meeting, elects directors By Investing.com - Investing.com South Africa
xeris biopharma holds annual meeting, elects directors - Investing.com
Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug - Crain's Chicago Business
Xeris Biopharma projects $1 billion Recorlev revenue by 2035 - Investing.com South Africa
Xeris Biopharma Holdings, Inc. Rings the Closing Bell - Nasdaq
Transcript : Xeris Biopharma Holdings, Inc.Analyst/Investor Day - marketscreener.com
Xeris Biopharma Holdings, Inc. Reaffirms Revenue Guidance for the Year 2025 - marketscreener.com
Xeris Biopharma Holdings Shares Fall; 2025 Revenue Guidance Reaffirmed, Long-Term Outlook Set - marketscreener.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day - mx.advfn.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation a - GuruFocus
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day | XERS Stock News - GuruFocus
Xeris Biopharma Holdings Reaffirms 2025 Revenue Guidance Of $260-$275 Million - marketscreener.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Holdings Lessened by Ameriprise Financial Inc. - Defense World
XERS: Key Highlights from Analyst and Investor Day | XERS Stock News - GuruFocus
ProShare Advisors LLC Cuts Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $273,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Bank of America Corp DE Sells 17,544 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Deutsche Bank AG Grows Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (NASDAQ:XERS) Cut to “Hold” at Wall Street Zen - Defense World
Northern Trust Corp Purchases 38,155 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) With A Potential Upside Of More Than 18.7% - Stocksregister
Jane Street Group LLC Decreases Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Announces Details for Analyst & Investor Day | XERS Stock News - GuruFocus
Xeris Announces Details for Analyst & Investor Day - Business Wire
Balyasny Asset Management L.P. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Announces Details for Analyst & Investor Day | User | poteaudailynews.com - FinancialContent
The Manufacturers Life Insurance Company Lowers Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma Q2 Earnings - Defense World
Voya Investment Management LLC Reduces Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Raymond James Financial Inc. Purchases New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Hsbc Holdings PLC Decreases Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Raised by Price T Rowe Associates Inc. MD - Defense World
Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.10 Consensus Target Price from Analysts - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):